Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP83UZ)

• Drug Name: Fumaric acid Drug Info
• Synonyms: Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 3	[1]
Pustular palmoplantar psoriasis	EA90	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 444972
  ChEBI ID: CHEBI:18012
  CAS Number: CAS 110-17-8
  TTD Drug ID: DMP83UZ

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[3]
VIR-201	DMAMIU4	Human immunodeficiency virus infection	1C62	Phase 1/2	[4]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[5]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[6]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[7]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[8]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[9]
TG-1042	DMS4BUK	B-cell lymphoma	2A86	Discontinued in Phase 2	[10]
VPM-4-001	DMZHAVG	Prostate cancer	2C82.0	Preclinical	[11]

Drug(s) Affected By Biotin--protein ligase (HLCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[12]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[2]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[14]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[16]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[17]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[18]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Binder	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Biotin--protein ligase (HLCS)	OTPDUX30	BPL1_HUMAN	Gene/Protein Processing	[2]

References

• [1] Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
• [2] Resveratrol compounds inhibit human holocarboxylase synthetase and cause a lean phenotype in Drosophila melanogaster. J Nutr Biochem. 2015 Nov;26(11):1379-84. doi: 10.1016/j.jnutbio.2015.07.004. Epub 2015 Jul 26.
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
• [5] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [6] Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
• [7] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [8] T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
• [9] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [10] Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
• [11] BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.
• [12] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [13] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [14] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [15] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [16] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [17] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [18] Chromium(VI) causes down regulation of biotinidase in human bronchial epithelial cells by modifications of histone acetylation. Toxicol Lett. 2011 Aug 28;205(2):140-5. doi: 10.1016/j.toxlet.2011.05.1032. Epub 2011 May 27.